Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol 2020;78:540–3

Research output: Contribution to journalLetterpeer-review

Abstract

We thank Funada et al for the comments on our Brief Correspondence in European Urology [1]. We agree that established guidelines for subgroup analyses are critical for promoting valid assessment of treatment effect heterogeneity and note that the comments (ie, the importance of clearly stating the post hoc nature of analysis, having a clear basis for undertaking the subgroup analysis, using a statistical test of treatment-by-covariate interaction, and cautious interpretation of findings) simply restate the existing appropriate methods, interpretation, and reporting in our manuscript [1]
Original languageEnglish
Pages (from-to)e227
Number of pages1
JournalEuropean Urology
Volume78
Issue number6
Early online date18 Sept 2020
DOIs
Publication statusPublished - Dec 2020

Keywords

  • Urothelial Carcinoma
  • heterogeneity
  • antibiotic use

Fingerprint

Dive into the research topics of 'Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol 2020;78:540–3'. Together they form a unique fingerprint.

Cite this